passages: 3513
passages: document
passages: The treatment of asthma in adults using sodium cromoglycate pressurized aerosol : a double-blind controlled trial . Sodium cromoglycate formulated as a pressurized aerosol ( 2 mg 4-times daily ) and placebo were compared in 31 adult asthmatic patients in a double-blind crossover trial lasting 12 weeks . Sodium cromoglycate was superior to placebo in improving breathlessness at rest ( p less than 0.001 ) , breathlessness on exertion ( p less than 0.05 ) and the quality of sleep ( p less than 0.001 ) , and also in improving the morning peak expiratory flow rate value ( p less than 0.05 ) . Both the patients ' ( p less than 0.05 ) and the clinicians ' ( p less than 0.01 ) treatment opinions , and their treatment preferences ( p less than 0.05 ) , favoured sodium cromoglycate . Moreover , usage of bronchodilators ( theophylline and aerosol beta-stimulants combined ) declined significantly ( p less than 0.001 ) during sodium cromoglycate treatment compared to placebo . No side-effects were reported . The results of this study show that sodium cromoglycate delivered by pressurized aerosol was significantly superior to placebo , not only in improving asthmatic symptoms , but also in reducing the amount of concomitant bronchodilator therapy required .
entities: 3514
entities: Intervention_Pharmacological
entities: sodium cromoglycate
entities: 3515
entities: Intervention_Pharmacological
entities: Sodium cromoglycate
entities: 3516
entities: Intervention_Control
entities: placebo
entities: 3517
entities: Intervention_Pharmacological
entities: Sodium cromoglycate
entities: 3518
entities: Intervention_Control
entities: placebo
entities: 3519
entities: Intervention_Pharmacological
entities: sodium cromoglycate .
entities: 3520
entities: Intervention_Pharmacological
entities: sodium cromoglycate
entities: 3521
entities: Intervention_Control
entities: placebo .
entities: 3522
entities: Intervention_Pharmacological
entities: sodium cromoglycate
entities: 3523
entities: Intervention_Control
entities: placebo
entities: 3524
entities: Outcome_Physical
entities: breathlessness at rest
entities: 3525
entities: Outcome_Physical
entities: breathlessness on exertion
entities: 3526
entities: Outcome_Physical
entities: quality of sleep
entities: 3527
entities: Outcome_Physical
entities: morning peak expiratory flow rate value
entities: 3528
entities: Outcome_Other
entities: treatment preferences
entities: 3529
entities: Outcome_Adverse-effects
entities: side-effects
entities: 3530
entities: Outcome_Physical
entities: asthmatic symptoms
entities: 3531
entities: Participant_Condition
entities: asthma
entities: 3532
entities: Participant_Age
entities: adults
entities: 3533
entities: Participant_Sample-size
entities: 31
entities: 3534
entities: Participant_Age
entities: adult
entities: 3535
entities: Participant_Condition
entities: asthmatic